HCA Healthcare EVP discloses stock, SARs stake
HCA’s chief clinical officer discloses his existing common stock and multiple stock appreciation right awards on an initial Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
HCA Healthcare, Inc. (HCA) reports the initial equity holdings of EVP and Chief Clinical Officer Michael J. Schlosser on a Form 3. As of September 1, 2026, he holds direct and indirect shares of common stock and a series of vested and vesting stock appreciation rights tied to HCA common stock.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Schlosser Michael J
Role
EVP and Chief Clinical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Appreciation Right F2 | -- | -- | -- |
| holding | Stock Appreciation Right F3 | -- | -- | -- |
| holding | Stock Appreciation Right F4 | -- | -- | -- |
| holding | Stock Appreciation Right F5 | -- | -- | -- |
| holding | Stock Appreciation Right F6 | -- | -- | -- |
| holding | Stock Appreciation Right F7 | -- | -- | -- |
| holding | Stock Appreciation Right F8 | -- | -- | -- |
| holding | Stock Appreciation Right F9 | -- | -- | -- |
| holding | Stock Appreciation Right F10 | -- | -- | -- |
| holding | Stock Appreciation Right F11 | -- | -- | -- |
| holding | Stock Appreciation Right F12 | -- | -- | -- |
| holding | Stock Appreciation Right F13 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Appreciation Right — 40,712 contracts (Direct);
Common Stock — 170.1027 shares (Direct);
Common Stock — 6,951 shares (Indirect, By 2022 Trust)
Footnotes (13)
- F1. Includes 170.1027 shares acquired under the Issuer's employee stock purchase plans.
- F2. The stock appreciation rights vested in four equal annual installments beginning on February 1, 2018.
- F3. The stock appreciation rights vested in four equal annual installments beginning on May 3, 2018.
- F4. The stock appreciation rights vested in four equal annual installments beginning on January 31, 2019.
- F5. The stock appreciation rights vested in four equal annual installments beginning on January 30, 2020.
- F6. The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.
- F7. The stock appreciation rights vested in four equal annual installments beginning on February 3, 2022.
- F8. The stock appreciation rights vested in four equal annual installments beginning on July 22, 2022.
- F9. The stock appreciation rights vested in four equal annual installments beginning on January 28, 2023.
- F10. The stock appreciation rights vest in four equal annual installments beginning on January 30, 2024.
- F11. The stock appreciation rights vest in four equal annual installments beginning on January 31, 2025.
- F12. The stock appreciation rights vest in four equal annual installments beginning on January 28, 2026.
- F13. The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027.
Key Figures
Direct common stock holdings: 170.1027 shares
Indirect common stock holdings: 6,951 shares
SAR underlying shares at $81.96: 3,030 shares
+4 more
7 metrics
Direct common stock holdings
170.1027 shares
Direct HCA common stock held by Michael J. Schlosser as of September 1, 2026
Indirect common stock holdings
6,951 shares
HCA common stock held indirectly by 2022 Trust as of September 1, 2026
SAR underlying shares at $81.96
3,030 shares
Stock appreciation right with $81.9600 exercise price expiring February 1, 2027
SAR underlying shares at $253.30
3,789 shares
Stock appreciation right with $253.3000 exercise price expiring January 30, 2033
SAR underlying shares at $482.53
3,103 shares
Stock appreciation right with $482.5300 exercise price expiring January 29, 2036
Earliest SAR grant vesting start
February 1, 2018
First SAR footnote states vesting began in four annual installments on this date
Latest SAR grant vesting start
January 29, 2027
Most recent SAR footnote states vesting begins in four annual installments on this date
Key Terms
Stock Appreciation Right, underlying security, indirect ownership, employee stock purchase plans
4 terms
Stock Appreciation Right financial
"The stock appreciation rights vested in four equal annual installments"
A stock appreciation right (SAR) is a form of employee pay that gives the holder the right to receive the increase in a company's share price over a set reference price, paid in cash or shares, without having to buy stock first. It matters to investors because SARs can create future cash outflows or dilute existing shareholders if settled in stock, and they align employee incentives with share-price performance like a bonus tied to a home's price rise.
underlying security financial
"underlying security title listed as Common Stock for each stock appreciation right"
indirect ownership financial
"Common Stock held indirectly with nature of ownership described as By 2022 Trust"
employee stock purchase plans financial
"Includes 170.1027 shares acquired under the Issuer's employee stock purchase plans"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does HCA (HCA) disclose in Michael J. Schlosser’s Form 3?
The filing discloses initial ownership for EVP and Chief Clinical Officer Michael J. Schlosser, including direct and indirect holdings of HCA common stock and multiple stock appreciation rights (SARs) with various exercise prices and expiration dates; it does not report any purchases or sales.
What indirect HCA common stock does Schlosser report on the Form 3?
He reports 6,951 shares of HCA common stock held indirectly with the nature of ownership described as "By 2022 Trust," indicating these shares are held through a 2022 Trust.
What stock appreciation rights tied to HCA common stock are reported?
Schlosser reports multiple stock appreciation rights, each referencing HCA common stock as the underlying security, with exercise prices ranging from $81.96 to $482.53 and expiration dates from February 1, 2027 through January 29, 2036.
Do the HCA stock appreciation rights in this Form 3 vest over time?
Yes. Footnotes state various SAR grants vest in four equal annual installments, with vesting schedules beginning on dates between February 1, 2018 and January 29, 2027, depending on the specific grant.
Are any Rule 10b5-1 trading plans mentioned in this HCA Form 3?
No. The data indicate no Rule 10b5-1 plan is reported for the holdings disclosed; the filing presents only existing ownership positions, not trades executed under a trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
